AQR Capital Management LLC Has $13.09 Million Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

AQR Capital Management LLC boosted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 4.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 47,954 shares of the medical research company's stock after acquiring an additional 1,864 shares during the period. AQR Capital Management LLC owned approximately 0.17% of Bio-Rad Laboratories worth $13,091,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Capital Advisors Ltd. LLC increased its position in shares of Bio-Rad Laboratories by 193.8% during the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock worth $26,000 after acquiring an additional 62 shares in the last quarter. Sound Income Strategies LLC bought a new position in Bio-Rad Laboratories during the 1st quarter worth about $38,000. EntryPoint Capital LLC acquired a new stake in shares of Bio-Rad Laboratories in the 1st quarter valued at about $51,000. Headlands Technologies LLC acquired a new position in shares of Bio-Rad Laboratories during the second quarter worth about $51,000. Finally, Parallel Advisors LLC grew its holdings in shares of Bio-Rad Laboratories by 36.8% during the fourth quarter. Parallel Advisors LLC now owns 171 shares of the medical research company's stock worth $55,000 after buying an additional 46 shares in the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the firm's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares of the company's stock, valued at approximately $48,582.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now directly owns 147 shares of the company's stock, valued at approximately $48,582.03. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Andrew J. Last sold 3,000 shares of the business's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares of the company's stock, valued at $2,494,016.46. The disclosure for this sale can be found here. 17.06% of the stock is owned by insiders.

Analyst Ratings Changes

BIO has been the subject of a number of recent research reports. StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Thursday, August 1st. Citigroup raised shares of Bio-Rad Laboratories from a "neutral" rating to a "buy" rating and raised their target price for the company from $350.00 to $400.00 in a research report on Tuesday. Royal Bank of Canada reissued an "outperform" rating and set a $401.00 price target on shares of Bio-Rad Laboratories in a research report on Friday, August 16th. Finally, Wells Fargo & Company began coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price objective for the company. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $368.20.

Bio-Rad Laboratories Stock Performance

BIO stock traded up $4.93 during trading hours on Wednesday, reaching $342.62. The stock had a trading volume of 267,396 shares, compared to its average volume of 255,186. The stock has a market capitalization of $9.77 billion, a PE ratio of -32.95 and a beta of 0.95. The stock has a 50-day simple moving average of $327.11 and a 200 day simple moving average of $307.07. Bio-Rad Laboratories, Inc. has a fifty-two week low of $261.59 and a fifty-two week high of $366.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.28 and a quick ratio of 4.63.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.99. The business had revenue of $638.50 million during the quarter, compared to the consensus estimate of $645.79 million. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. Bio-Rad Laboratories's revenue was down 6.3% on a year-over-year basis. During the same period last year, the business posted $3.00 EPS. Analysts predict that Bio-Rad Laboratories, Inc. will post 10.31 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.